Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124572
Filing Date
2024-11-12
Accepted
2024-11-12 07:25:20
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dyn-20240930.htm   iXBRL 10-Q 2308687
2 EX-10.1 dyn-ex10_1.htm EX-10.1 155892
3 EX-10.2 dyn-ex10_2.htm EX-10.2 73759
4 EX-10.3 dyn-ex10_3.htm EX-10.3 74276
5 EX-31.1 dyn-ex31_1.htm EX-31.1 12279
6 EX-31.2 dyn-ex31_2.htm EX-31.2 11899
7 EX-32.1 dyn-ex32_1.htm EX-32.1 6308
8 EX-32.2 dyn-ex32_2.htm EX-32.2 6226
9 GRAPHIC img72420619_0.jpg GRAPHIC 15344
  Complete submission text file 0000950170-24-124572.txt   7173212

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dyn-20240930.xsd EX-101.SCH 787855
60 EXTRACTED XBRL INSTANCE DOCUMENT dyn-20240930_htm.xml XML 1000191
Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451
Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company filings)

EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39509 | Film No.: 241443281
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)